$IRD

Opus Genetics, Inc.

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and other therapies for eye disorders. Its pipeline includes seven adeno-associated virus gene therapy programs targeting mutations in LCA5, BEST1, RHO, CNGB1, RDH12, NMNAT1 and MERTK. The company is also developing Phentolamine Ophthalmic Solution 0.75%, a small-molecule eye drop that is FDA-approved to reverse pharmacologically induced pupil dilation and is being developed for presbyopia and low-light vision disturbances after refractive surgery. Its gene therapies are administered by subretinal injection. Opus makes money through licensing and collaboration arrangements, including an agreement granting Viatris rights to develop and commercialize Phentolamine Ophthalmic Solution 0.75% in most markets; Viatris handles commercialization for approved indications. Opus is headquartered in Durham, North Carolina.

3
0
0
—
$329K
YERXA BENJAMIN R
17%
See all $IRD insider activity →

Citizens reiterates Opus Genetics stock rating on pipeline progress

Citizens reiterated a Market Outperform rating and $17.00 price target for Opus Genetics (IRD). The stock is up 115% over the past year but is considered overvalued. The company reported Q3 revenue of $1.1M, missing estimates. Citizens assigns 40% and 80% success probabilities to OPGx-BEST1 and OPGx-LCA5, respectively, with peak sales estimates of over $3B and $100M.

IRD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning IRD (Opus Genetics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.

Recent IRD coverage spans technology, earnings and insider activity.

In the last 30 days, IRD insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($329K). The most active reporter was YERXA BENJAMIN R, President, with 2 filings. 17% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving IRD

AlphAI scores every news story that mentions IRD with an AI model for sentiment and relevance, and aggregates insider trades from Opus Genetics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IRD

Score

Citizens reiterates Opus Genetics stock rating on pipeline progress

Citizens reiterated a Market Outperform rating and $17.00 price target for Opus Genetics (IRD). The stock is up 115% over the past year but is considered overvalued. The company reported Q3 revenue of $1.1M, missing estimates. Citizens assigns 40% and 80% success probabilities to OPGx-BEST1 and OPGx-LCA5, respectively, with peak sales estimates of over $3B and $100M.

Opus Genetics misses Q3 estimates on revenue and earnings

Opus Genetics (IRD) reported Q3 revenue of $1.1M, missing estimates of $1.54M, and adjusted EPS of -$0.46, worse than the expected -$0.14. Revenue declined 64% YoY, driven by lower R&D reimbursement from Viatris. Net loss widened to $46.5M. The company cited advancements in gene therapy programs and expects cash runway into 2029. Shares fell 1.43% in pre-market trading.

$IRDHighAI 8/10Earnings

Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update

Opus Genetics, Inc. (IRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Cle

$IRDMedAI 8/10

Opus Genetics completes dosing in gene therapy trial cohort

Opus Genetics (IRD) completed dosing in Cohort 2 of its BIRD-1 trial for OPGx-BEST1, treating 11 participants with a higher dose than Cohort 1. Data is expected in Q1 2027, with Phase 3 potentially starting in H2 2027. Cohort 1 showed improvements in visual measures with no serious adverse events. The FDA aligned on a pivotal endpoint for the therapy, which targets BEST1-related retinal diseases with no current approved treatments.

Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval

Opus Genetics (NASDAQ:IRD) is advancing clinical trials for gene therapies OPGx-LCA5 and OPGx-BEST1. The company expects data readouts by late 2024 and projects a cash runway into 2029. Opus estimates addressable populations of 150-200 for LCA5 and 23,600 for BEST1 in the U.S. Management anticipates potential priority review vouchers and plans to prioritize programs based on clinical evidence.

Related tickers